KLOW results, one drug at a time
Studies tracked blood flow, wound closure, and thymosin beta-4 repair. Keep each result with the one drug tested, not the KLOW mix.
The short version: why the mix has no result yet
Researchers first studied four short protein chains because wounds need several kinds of help. New blood vessels bring oxygen and food, skin cells cross the wound, and collagen gives new tissue strength. The immune system must also calm down at the right time. Three drugs caused vessel growth in animals or lab dishes. KPV calmed swelling in the gut. Those findings led people to discuss a four-drug mix, though no study has shown teamwork among the drugs. Here, KLOW results means a separate result for each drug. It doesn't mean KLOW healed a person's knee, tendon, skin, or bowel. Keep that limit beside each figure when you judge its value for your own choice.
What the detailed BPC-157 studies reported
The most mechanistically detailed angiogenesis result for BPC-157 is the 2017 Hsieh et al. study: BPC-157 upregulated VEGFR2 (vascular endothelial growth factor receptor 2) expression in human vascular endothelial cells and rat hindlimb ischemia models, promoted VEGFR2 internalization with downstream PI3K/Akt/eNOS pathway activation, increased vessel density in the chick chorioallantoic membrane model, and accelerated blood-flow recovery in ischemic muscle [8]. Effects were blocked by endocytosis inhibition, indicating that receptor internalization is a mechanistically required step. VEGFR2 phosphorylation is the same node that exogenous VEGF activates — BPC-157 approaches it from a different ligand route.
Those findings still belong to the separate components of KLOW, not the blend. For KLOW blend injections, prescription care appears in the catalogue at mypromise.com; Promise Peptides prescribes only when the reviewing clinician, licensed in the U.S., accepts the patient's case. Requests can end without a prescription. The service is for patients in the U.S. only; their state and requested treatment set the options. The compounded KLOW product has no FDA approval.
Earlier work by Cerovecki and Brcic et al. (2009) directly measured BPC-157's modulatory effect on angiogenesis during muscle and tendon healing in rats, linking the peptide's established tendon-repair outcomes to concurrent enhanced vascularization of the healing tissue [12]. In the 2003 Staresinic et al. transected-Achilles rat study, improved tendon healing across all measured endpoints was accompanied by improved tissue architecture [2] — the angiogenic component of that repair is consistent with the 2017 VEGFR2 mechanism data.
What GHK-Cu changed in burned skin
A 1994 study looked at a support protein found around cells. When the body cut that protein into pieces, some pieces could hold copper. GHK was one of them. In animals and cells kept in dishes, those pieces helped blood-vessel cells grow [11]. The pieces worked even when no copper had been added first. That suggests the protein pieces themselves may aid vessel repair. It doesn't show that KLOW will mend your wound.
A 2017 study tested GHK-Cu on burns in mice. Researchers wrapped GHK-Cu in tiny fat pockets to help it reach the wound. The burns closed about 14 days sooner than untreated burns. Treated human blood-vessel cells grew 33.1% more than untreated cells in a dish [10]. The paper's growth message number 2 tells blood-vessel cells to grow. BPC-157 wasn't part of this study. The fat-wrapped form worked better than plain GHK-Cu. How the drug reached the wound may therefore have shaped the result.
What TB-500 and thymosin beta-4 changed in wounds
A key 1999 rat study used thymosin beta-4, the full protein behind TB-500. New skin covered 42% more wound area at 4 days. By 7 days, the gain reached 61%. Wounds also pulled shut at least 11% more by day 7. The tissue grew blood vessels and laid down more collagen. An amount of just 10 trillionths of a gram made skin cells move 2–3-fold, meaning several times as much, in a dish [1]. Those are rat and cell findings, not KLOW results in people or in your body.
A 2004 rodent study found that full thymosin beta-4 helped wounds, new vessels, and hair roots at the same time [9]. In 2025, researchers packed full thymosin beta-4 into tiny bubbles made by cells. A wet dressing carried those bubbles into wounds, where blood vessels grew [14]. A 2024 review said the full protein also helps the body finish its swelling response [15].
TB-500 is the short drug. Far less work has tested its effect on blood-vessel growth. You can't give TB-500 credit for every result from full thymosin beta-4, especially when weighing a claim about your wound.
What KPV changed in a swollen gut
KPV hasn't been shown to make new blood vessels. Researchers studied it because it can calm parts of the immune response. In 2008, a small opening in human immune cells and gut cells let KPV enter. Once inside, KPV lowered some of the body's calls for swelling. Mice with a sore, swollen bowel also improved after drinking KPV [3]. That study watched cells and mice, not KLOW.
A swollen gut can run short of oxygen and leak fluid from small vessels. Calming the immune response might give the tissue a better place to heal. That is why researchers think KPV might fit with the other drugs. They haven't tested the drugs as a team or shown that KPV stops leaks in people's gut vessels. If gut comfort matters to you, the study only says swelling eased in mice. It leaves your response to KLOW unanswered.